Completion of ASN-002 Nodular Basal Cell Carcinoma (nBCC) Trial, key regulatory milestones and recruitment of US Clinical Advisors

December 14th 2017

Ascend announced the completion of its dose escalation phase 1/2 clinical trial in patients treated with ASN-002. The study reported excellent clinical outcomes.

Press Release: Ascend completes ASN-002 Nodular Basal Cell Carcinoma (nBCC) Trial

News